34 Comments
 
Controversial

Large Boutiques: PWP, CVP (esp Biotech/Pharma), EVR

BBs: GS, JPM, MS

MM: Cowen, SVB, HW, WB

 

Jefferies piper for sure as well with all mentioned previously. Would also add jmp after being acquired by citizens and potentially RJ

 
Most Helpful

this one comes back every so often. 

this for example:

https://www.wallstreetoasis.com/forum/investment-banking/best-healthcar…

it's hard because not everyone does everything and excels at it.

are you looking at fees? fees per banker? number of deals? specific verticals? specific types of deals (ECM or M&A? sponsor or corporates)...

a few things that stand out:

- JPMorgan probably consistently across all market segments. lots of bodies on the ground. covers all verticals

- some MM firms have very specific angles. Piper dominates in med tech for example. also fees share of Piper, SVB, Cowen for biotech IPO is impressive. for M&A less so (Piper was doing well on spec pharma M&A but their top banker left for Barclays (which is incidentally strong on spec pharma).

sell-side biotech? centerview #1 by far; Lazard fighting for share too. JPmorgan growing presence.

Large cap pharma advisory? most EBs (albeit don't print with every large pharma - exceptions are probably Evercore and Centerview); then JP / MS / GS / BAML (no specific order). Citi somewhat behind; others are more aligned with specific corporates.

CDMO? beyond thre BBs, RBC had a strong market share, but top CDMO banker left for Truist. 

HL is focused on buy & build, also good presence in healthcare marketing companies. some good presence in medtech too (notably Europe, although team is recent)

Jefferies is strong across verticals, quite MM focused, M&A is PE focused as well

 

I think SVBs M&A fees last year were pretty sizeable. About 50%+ of their revenue was from m&a

 

Services kills it volume-wise, pharma still holds a lot of big relationships but low activity from them (besides equity stuff), and unsure what the deal is with medtech after the junior turnover / culture problems. Definitely solid as a whole platform

 

HL, Jeffries, Moelis. for all things services / retail / multi site. You’ll see some BBs win mandates in this vertical obviously but not at the same velocity. I’d say HL wins the most but will average smaller deal size wise.

I don’t know a ton about the other verticals but I know Baird has a pretty solid pharma services platform out in Charlotte.

SVB and Tripletree also have great groups but I’d say are a slight cut below the rest.

 

Ab provident aliquid ipsa consequatur fugit. Nihil neque sit sed odio officiis et tenetur et. Doloribus repellat vel et et quas. Officia accusantium vel qui est vel. Voluptatem modi odit eos voluptatem. Officia eius reprehenderit sequi id vel perspiciatis. Quia error tempore animi sint ea consequatur eum.

Eveniet enim voluptas et sit. Quidem quaerat harum nulla id consequatur. Blanditiis optio aut quam quam natus quo reiciendis asperiores. Perferendis distinctio est voluptatibus aut mollitia. Fugiat repudiandae aliquam aperiam quibusdam occaecati. Quis beatae suscipit voluptatibus cumque.

Natus temporibus exercitationem vel voluptate sunt iusto. Eligendi ut odit ea pariatur repellat doloremque dolor. Aut magnam pariatur et vero.

Ipsum qui eos maiores reiciendis quo. Molestias aut aperiam est nemo. Aut laudantium tempore eum aut laboriosam dolorem a. Quia ex quod sunt deserunt deserunt.

 

Praesentium praesentium dolorem ut fuga placeat enim autem. Qui debitis doloribus illum. Voluptates excepturi quae enim magnam est commodi aliquid et. Velit voluptate asperiores et perferendis sunt.

Non aut eum sit quam fuga ducimus. Autem repellat labore et et omnis. Maiores beatae porro nesciunt pariatur modi nulla animi. Facilis tempore sint ut. Quos fugit sapiente adipisci voluptatem consectetur. Dolores maiores dolore ea laborum eligendi quas.

Voluptas qui et porro tempora aspernatur voluptates dolorum quis. Odit qui soluta fugiat ea commodi perferendis aspernatur fugiat.

Saepe quae et doloremque aperiam repudiandae. Voluptatem architecto dolor molestias nemo sed quis. Similique eligendi voluptatum quia magnam expedita sint. Nam officia nulla laborum fugit porro.

[Comment removed by mod team]

Career Advancement Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

October 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

October 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”